Department, of Clinical Haematology, Peter MacCallum Cancer/Royal Melbourne Hospital, Parkville, Australia.
Australian Cancer Research Fund Translational Research Laboratory, Royal Melbourne Hospital, Parkville, Australia.
Leuk Lymphoma. 2021 Jun;62(6):1482-1489. doi: 10.1080/10428194.2021.1872072. Epub 2021 Jan 31.
Poor Graft Function (PGF) is defined by multi-lineage cytopenias with complete donor chimerism post allogeneic transplantation, Risk factors for and subsequent mortality from PGF were assessed in our transplant cohort. Non-sibling donor [OR 1.97; 95% CI 1.02-3.70], ICU admission [OR 5.28; 95% CI 2.29-11.88] or blood culture positivity within the first 30 days [OR 1.67; 95% CI 1.07-2.62], grade III-IV acute graft vs host disease (GVHD) [OR 4.082; 95% CI 2.31-7.16] and CMV viremia [OR 2.43; 95% CI 1.53-3.88] and were significantly associated with development of PGF. PGF patients without count recovery had a 2 year OS of 6%. Severe GVHD, thrombocytopenia and anemia portended inferior survival and were used to develop a prognostic score for mortality from PGF. This analysis identifies risk factors predictive of PGF and poor survival in those without recovery.
移植物功能不良（PGF）定义为异基因移植后完全供者嵌合的多系细胞减少症。我们在移植队列中评估了 PGF 的风险因素及其随后的死亡率。非亲缘供体[比值比 1.97；95%置信区间 1.02-3.70]、重症监护病房入院[比值比 5.28；95%置信区间 2.29-11.88]或在最初 30 天内血培养阳性[比值比 1.67；95%置信区间 1.07-2.62]、III-IV 级急性移植物抗宿主病（GVHD）[比值比 4.082；95%置信区间 2.31-7.16]和 CMV 病毒血症[比值比 2.43；95%置信区间 1.53-3.88]与 PGF 的发生显著相关。无计数恢复的 PGF 患者 2 年 OS 为 6%。严重的 GVHD、血小板减少和贫血预示着生存不良，并用于开发 PGF 死亡率的预后评分。该分析确定了 PGF 和无恢复患者不良生存的预测因素。
